



SONGKLANAGARIND HOSPITAL
FACULTY OF MEDICINE
PRINCE OF SONGKLA UNIVERSITY
HATYAI SONGKHLA
THAILAND

HOSPITAL-BASED CANCER REGISTRY

SONGKLANAGARIND HOSPITAL ANNUAL REPORT 2011



EDITED BY
PARADEE PRECHAWITTAYAKUL, B.Sc.
June, 2013



SONGKLANAGARIND TUMOR REGISTRY
<http://medinfo2.psu.ac.th/cancer>

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT 2011

SONGKLANAGARIND HOSPITAL
FACULTY OF MEDICINE
PRINCE OF SONGKLA UNIVERSITY
HATYAI SONGKHLA
THAILAND

EDITOR
PARADEE PRECHAWITTAYAKUL, B.Sc.
June, 2013

Songklanagarind Tumor Registry
<http://medinfo2.psu.ac.th/cancer>

CONTENTS

Contents.....	i
Cancer Registry Staff	V
Flow Chart of the Songklanagarind Cancer Registry.....	VI
Flow Chart of the Songklanagarind Cancer Registry Report.....	VII
Summary.....	VIII
Table 1: Number of Patients in Songklanagarind Hospital.....	1
Table 2: Patient Categories of diagnosis and treatment.....	2
Table 3: Distribution of Referral Hospitals.....	3
Table 4: Distribution of Patient Payment Used.....	3
Table 5: Cancer Cases by Province of Residence.....	5
Table 6: Distribution of all newly diagnosed cancer cases by age and sex.....	6
Table 7: Distribution of Cases According to Method of Diagnosis.....	7
Table 8: Percentage of Morphologically Verified Cases (%MV)	7
Table 9: Distribution of Patients According to Type of Treatment.....	10
Table 10: The 10 Leading Sites of Cancer in Both Sexes.....	11
Table 11: The 10 Leading Sites of Cancer in Males.....	12
Table 12: The 10 Leading Sites of Cancer in Females.....	13
Table 13: Malignancy in Childhood.....	14

COMMON CANCERS

Oral Cavity Cancer

Table 14: Methods of Diagnosis.....	15
Table 15: Staging.....	16
Table 16: Types of Treatment.....	16

Esophageal Cancer

Table 17: Methods of Diagnosis.....	17
Table 18: Staging.....	18
Table 19: Types of Treatment.....	18

Colon and Rectum Cancer

Table 20: Methods of Diagnosis.....	19
Table 21: Staging.....	20
Table 22: Types of Treatment.....	21

Liver Cancer

Table 23: Methods of Diagnosis.....	22
Table 24: Types of Treatment.....	23

Lung Cancer

Table 25: Methods of Diagnosis.....	24
Table 26: Staging	25
Table 27: Types of Treatment.....	26

Breast Cancer (Excluding in Situ)

Table 28: Methods of Diagnosis.....	27
Table 29: Staging.....	28
Table 30: Types of Treatment.....	29

Cervical Cancer (Excluding in Situ)

Table 31: Methods of Diagnosis.....	30
Table 32: Staging.....	30
Table 33: Types of Treatment.....	30

Endometrial Cancer

Table 34: Methods of Diagnosis.....	33
Table 35: Staging	33
Table 36: Types of Treatment.....	34

Non-Hodgkin Lymphoma

Table 37: Methods of Diagnosis.....	35
Table 38: Distribution of Sites.....	35
Table 39: Types of Treatment.....	37

INTERESTING TUMOR

Gastrointestinal Stromal Tumor(GIST)

Table 40: Number of Cases in 5 Year	38
Table 41: Distribution of Site; 2007-2011	39

Neuroendocrine Tumor(NET)

Table 42: Number of Cases in 5 Year	40
Table 43: Distribution of Site; 2007-2011	41
Table 44: Sex and Age Distribution	42
Table 45: Histological Types	56

APPENDIX: Definitions	75
------------------------------------	----

ILLUSTRATIONS

FIGURE 1:	Trend of New Cancer Cases in Songklanagarind Hospital	1
FIGURE 2:	New Cancer Cases as a Percentage Year by Year	1
FIGURE 3:	Number of New Cancer Cases by Month	2
FIGURE 4:	Patient Categories of Diagnosis and Treatment	2
FIGURE 5:	Distribution of Referral Hospitals	3
FIGURE 6:	Percentage of Patient Payment Used	4
FIGURE 7:	Trends of Patients Payment Used; Percentage	4
FIGURE 8:	Distribution of Religion in Cancer Patients: Percentage	4
FIGURE 9:	Percentage of Patient by Residence	5
FIGURE 10:	Age Distribution of all Malignancies	6
FIGURE 11:	Methods of Diagnosis	7
FIGURE 12:	Types of Treatment	10
FIGURE 13:	Ten Year Trends of Cancer Treatment	11
FIGURE 14:	The 10 Leading Sites of Cancer in Both Sexes	11
FIGURE 15:	The 10 Leading Sites of Cancer in Males	12
FIGURE 16:	Trends of Five Leading Sites in Males: Number & Percent	13
FIGURE 17:	The 10 Leading Sites of Cancer in Females	13
FIGURE 18:	Trends of Five Leading Sites in Females: Number & Percent	13
FIGURE 19:	Age Distribution of all Malignancies in Childhood	14
<i>Oral Cavity Cancer</i>		
FIGURE 20:	Distribution of Sub sites	15
FIGURE 21:	Age Distribution	15
FIGURE 22:	Trends of Oral Cavity Cancer in Males and Females	16
<i>Esophageal Cancer</i>		
FIGURE 23:	Distribution of Sub sites in Both Sexes	17
FIGURE 24:	Age Distribution	17
FIGURE 25:	Trends of Esophageal Cancer in Males and Females	18
<i>Colon and Rectum Cancer</i>		
FIGURE 26:	Distribution of Sub sites in Both Sexes	19
FIGURE 27:	Age Distribution	19
FIGURE 28:	Age Distribution ; 2007-2011	20
FIGURE 29:	Trends of Colon and Rectum Cancer in Males and Females	21

Liver Cancer

FIGURE 30:	Distribution of Sub sites	22
FIGURE 31:	Age Distribution	22
FIGURE 32:	Trends of Liver Cancer in Males and Females	23

Lung Cancer

FIGURE 33:	Distribution of Sub sites	24
FIGURE 34:	Distribution of Sides in Both Sexes	24
FIGURE 35:	Age Distribution	25
FIGURE 36:	Trends of Lung Cancer in Males and Females	26

Breast Cancer (Excluding in Situ)

FIGURE 37:	Distribution of Sub sites in Females	27
FIGURE 38:	Age Distribution	27
FIGURE 39:	Age Distribution of Female Breast Cancer: 2007-2011	28
FIGURE 39:	Trend of Female Breast Cancer	28
FIGURE 41:	Trends of Female Breast Cancer By Stage: 2002-2011	29

Cervical Cancer (Excluding in Situ)

FIGURE 42:	Age Distribution	31
FIGURE 43:	Age Distribution of Cervical Cancer: 2007-2011	31
FIGURE 44:	Trends of Cervical Cancer	31
FIGURE 45:	Trends of Cervical Cancer By Stage: 2002-2011	32

Endometrial Cancer

FIGURE 46:	Age Distribution	33
FIGURE 47:	Trend of Endometrial Cancer	34

Non-Hodgkin Lymphoma

FIGURE 50:	Age Distribution	35
FIGURE 51:	Trends of Non-Hodgkin Lymphoma in Males and Females	37

INTERESTING TUMOR

Gastrointestinal Stromal Tumor(GIST)

FIGURE 50:	Distribution of Cases in 5 Year; 2007-2011	38
FIGURE 51:	Age Distribution; Accumulated 2007-2011	38


Neuroendocrine Tumor(NET)

FIGURE 52:	Distribution of Cases in 5 Year; 2007-2011	40
FIGURE 53:	Age Distribution; Accumulated 2007-2011	40


CANCER REGISTRY STAFF

MISS PARADEE	PRECHAWITTAYAKUL	NURSE
MISS BENJAPORN	CHUMSEANG	REGISTRAR
MRS. RATTANA	SUWANNO	REGISTRAR
MISS WANDEE	SRITONGKAEW	REGISTRAR
MRS. PARICHAD	PANCHALERM	REGISTRAR

FLOW CHART OF THE SONGKLANAGARIND CANCER REGISTRY



FLOW CHART OF THE SONGKLANAGARIND CANCER REGISTRY REPORT



S U M M A R Y

From January to December 2011, among 888,714 patients who attended Songklanagarind Hospital, 5,541 cases were new cancer patients. Males accounted for 2,716 cancer cases (49.0%). The three most payment used were universal coverage (47.2%) government/state enterprise (16.3%) and self payment (17.3%) respectively. The three most common sites, disregarding sex, were the lung (716 cases, 12.9%), breast (589 cases, 10.6%) and liver (429 cases, 7.7%). The three most common primary sites in males were the lung (17.7%), liver (11.6%) and colon & rectum (8.1%). The three most common primary sites in females were the breast (20.9%), uterine cervix (13.7%) and lung (8.3%). There were 118 cases (2.1%) of childhood malignancy of which the most common type was leukemia.

The percentage of histologically confirmed cases was 82.5% in males and 91.1% in females. The three most common provinces of residence were Songkhla, Nakhon Si Thammarat and Phattalung.

TABLE 1: NUMBER OF PATIENTS IN SONGKLANAGARIND HOSPITAL

TYPE OF PATIENTS	NUMBER OF CASES
Total patients at OPD	888,714
New patients of hospital	32,250
New cancer patients	5,541

FIGURE 1: TREND OF NEW CANCER CASES IN SONGKLANAGARIND HOSPITAL




FIGURE 2: NEW CANCER CASES AS A PERCENTAGE OF YEAR OVER YEAR




FIGURE 3: NUMBER OF NEW CANCER CASES BY MONTH




TABLE 2: PATIENT CATEGORIES OF DIAGNOSIS AND TREATMENT

PATIENT CATEGORY	NUMBER	PERCENT
Diagnosed(other), treated(here*)	1,634	29.5
Diagnosed(here*), treated(here*)	1,478	26.7
Diagnosed(other), no treated	822	14.8
Diagnosed(other), treated(other&here*)	767	13.8
Diagnosed(here*) only	580	10.4
Diagnosed(other), treated(other)	260	4.7
Total	5,541	100.0

*Here means Songklanagarind hospital.

FIGURE 4: PATIENT CATEGORIES OF DIAGNOSIS AND TREATMENT




TABLE 3: DISTRIBUTION OF REFERRAL HOSPITALS

REFERRAL HOSPITAL	NUMBER	PERCENT
Government hospital in Southern area	3002	86.2
Private hospital or clinic in Southern area	300	8.6
Hospital in Bangkok	131	3.8
Hospital in other area	24	0.7
Hospital in other countries	8	0.2
Not specified	18	0.5
TOTAL	3,483	100.0

FIGURE 5: DISTRIBUTION OF REFERRAL HOSPITALS




TABLE 4: DISTRIBUTION OF PATIENT PAYMENT USED

PATIENT PAYMENT USED	NUMBER	PERCENT
Universal Coverage	2,615	47.2
Government/State Enterprise	901	16.3
Self payment	968	17.5
Social Security	283	5.1
Others	32	0.6
Not specified	742	13.4
TOTAL	5,541	100.0

FIGURE 6: PERCENTAGE OF PATIENT PAYMENT USED




FIGURE 7: TRENDS OF PATIENT PAYMENT USED: PERCENTAGE




FIGURE 8: DISTRIBUTION OF RELIGION IN CANCER PATIENTS: PERCENTAGE




TABLE 5: CANCER CASES BY PROVINCE OF RESIDENCE

AREA	NUMBER	PERCENT
Non-Southern Provinces	76	1.4%
Ranong	35	0.6%
Chumphon	75	1.4%
Phangnga	143	2.6%
Phuket	195	3.5%
Surat Thani	203	3.7%
Satun	219	4.0%
Yala	236	4.3%
Krabi	266	4.8%
Narathiwat	278	5.0%
Pattani	340	6.1%
Trang	451	8.1%
Phatthalung	518	9.3%
Nakhon Si Thammarat	1,046	18.9%
Songkhla	1,460	26.3%
TOTAL	5,541	100.0%



FIGURE 9: PERCENTAGE OF PATIENT BY RESIDENCE




TABLE 6: DISTRIBUTION OF ALL NEWLY DIAGNOSED CANCER CASES BY AGE AND SEX

AGE GROUP	Male		Female		Both sex	
	NO.	% OF ALL CANCER	NO.	% OF ALL CANCER	NO.	% OF ALL CANCER
0-	31	0.6%	21	0.4%	64	1.2%
5-	23	0.4%	11	0.2%	31	0.6%
10-	16	0.3%	16	0.3%	42	0.8%
15-	30	0.5%	28	0.5%	46	0.8%
20-	19	0.3%	40	0.7%	59	1.1%
25-	28	0.5%	49	0.9%	101	1.8%
30-	52	0.9%	111	2.0%	160	2.9%
35-	87	1.6%	182	3.3%	282	5.1%
40-	130	2.3%	274	4.9%	379	6.8%
45-	212	3.8%	350	6.3%	513	9.3%
50-	300	5.4%	370	6.7%	610	11.0%
55-	348	6.3%	351	6.3%	620	11.2%
60-	346	6.2%	263	4.7%	570	10.3%
65-	307	5.5%	243	4.4%	517	9.3%
70-	323	5.8%	222	4.0%	583	10.5%
75-	264	4.8%	153	2.8%	401	7.2%
80-	137	2.5%	88	1.6%	265	4.8%
85+	63	1.1%	53	1.0%	116	2.1%
	2,716	49.0%	2,825	51.0%	5,541	100.0%

Male age; mean = 59.24, median = 61

Female age; mean = 53.90, median = 54

FIGURE 10: AGE DISTRIBUTION OF ALL MALIGNANCIES




TABLE 7: DISTRIBUTION OF CASES ACCORDING TO METHOD OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE		FEMALE	
	NO.	% IN MALES	NO.	% IN FEMALES
Clinical only	18	0.7%	13	0.5%
Clinical investigation and imaging	259	9.5%	139	4.9%
Surgery without histology	2	0.1%	1	0.04%
Specific biochemistry	130	4.8%	51	1.8%
Cytology or hematology	30	1.1%	49	1.7%
Histology of metastasis	35	1.3%	21	0.7%
Histology of primary	2242	82.6%	2550	90.2%
	2,716	100.0%	2,824	100.0%

FIGURE 11: METHODS OF DIAGNOSIS




TABLE 8: PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	PRIMARY SITE	Male			Female			All		
		Number		%MV	Number		%MV	Number of		%MV
		ALL	Confirmed		ALL	Confirmed		ALL	Confirmed	
C00	Lip	3	3	100.0%	12	12	100.0%	15	15	100.0%
C01-C02	Tongue	86	86	100.0%	25	25	100.0%	111	111	100.0%
C03-C06	Mouth	89	89	100.0%	33	32	96.9%	122	121	99.2%
C07-C08	Salivary gland	11	10	90.9%	14	14	100.0%	25	24	96.0%
C09	Tonsil	31	31	100.0%	5	4	80.0%	36	35	97.2%
C10	Oropharynx	20	20	100.0%	4	4	100.0%	24	24	100.0%
C11	Nasopharynx	81	80	98.8%	28	27	96.4%	109	107	98.2%

TABLE 8: (CONT) PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	PRIMARY SITE	Male			Female			All		
		Number		%MV	Number		%MV	Number		%MV
		of Histo.	%MV		of Histo.	%MV		of Histo.	%MV	
		ALL	Confirmed	In Males	ALL	Confirmed	In Females	ALL	Confirmed	Sex
C12-C13	Hypopharynx	66	66	100.0%	5	5	100.0%	71	71	100.0%
C14	Pharynx, unspecified	3	3	100.0%	3	3	100.0%	6	6	100.0%
C15	Esophagus	154	147	95.5%	22	22	100.0%	176	169	96.0%
C16	Stomach	49	48	98.0%	29	28	96.6%	78	76	97.4%
C17	Small intestine	10	8	80.0%	4	3	75.0%	14	11	78.6%
C18	Colon	104	101	97.1%	80	73	91.3%	184	174	94.6%
C19-C20	Rectum	116	112	96.6%	73	73	100.0%	189	185	97.9%
C21	Anus	5	5	100.0%	7	7	100.0%	12	12	100.0%
C22	Liver	314	59	18.8%	115	25	21.7%	429	84	19.6%
C23-C24	Gallbladder etc.	32	23	71.9%	33	25	75.8%	65	48	73.8%
C25	Pancreas	48	23	47.9%	43	20	46.5%	91	43	47.3%
C30-C31	Nose, sinuses etc.	14	13	92.9%	13	13	100.0%	27	26	96.3%
C32	Larynx	108	108	100.0%	2	1	50.0%	110	109	99.1%
C33-C34	Bronchus and lung	482	434	90.0%	234	213	91.0%	716	647	90.4%
C37-C38	Other thoracic organs	12	11	91.7%	3	2	66.7%	15	13	86.7%
C40-C41	Bone	17	11	64.7%	13	11	85.7%	30	22	74.2%
C43	Melanoma of skin	12	12	100.0%	12	12	100.0%	23	23	100.0%
C44	Other skin	59	59	100.0%	40	40	100.0%	99	99	100.0%
C46	Kaposi sarcoma	0	0	0.0%	0	0	0.0%	0	0	#DIV/0!
C47; C49	Connective and soft tissue	44	43	97.7%	41	36	87.8%	85	79	92.9%
C50	Breast	0	0	0.0%	589	585	99.3%	589	585	99.3%
C51	Vulva	0	0	0.0%	15	14	93.3%	15	14	93.3%
C52	Vagina	0	0	0.0%	11	11	100.0%	11	11	100.0%
C53	Cervix uteri	0	0	0.0%	388	385	99.2%	388	385	99.2%
C54	Corpus uteri	0	0	0.0%	156	156	100.0%	156	156	100.0%
C55	Uterus unspecified	0	0	0.0%	15	15	100.0%	15	15	100.0%
C56	Ovary	0	0	0.0%	185	167	90.3%	185	167	90.3%
C57	Other female genital	0	0	0.0%	7	6	85.7%	7	6	85.7%

TABLE 8: (CONT) PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	PRIMARY SITE	Male			Female			All		
		Number of Histo.		%MV	Number of Histo.		%MV	Number of Histo.		%MV
		ALL	Confirmed		ALL	Confirmed		ALL	Confirmed	
C58	Placenta	0	0	0.0%	16	7	43.8%	16	7	43.8%
C60	Penis	21	20	95.2%	0	0	0.0%	21	20	95.2%
C61	Prostate	106	94	88.7%	0	0	0.0%	106	94	88.7%
C62	Testis	12	9	75.0%	0	0	0.0%	12	9	75.0%
C63	Other male genital	1	1	100.0%	0	0	0.0%	1	1	100.0%
C64	Kidney	33	27	81.8%	14	12	85.7%	47	39	83.0%
C65	Renal pelvis	3	3	100.0%	0	0	0.0%	3	3	100.0%
C66	Ureter	3	3	100.0%	3	1	33.3%	6	4	66.7%
C67	Bladder	65	64	98.5%	13	12	92.3%	78	76	97.4%
C68	Other urinary organs	1	1	100.0%	0	0	0.0%	1	1	100.0%
C69	Eye	10	7	70.0%	11	9	81.8%	21	16	76.2%
C70-C72	Brain, nervous system	58	47	81.0%	35	31	88.6%	93	78	83.9%
C73	Thyroid	46	41	89.1%	178	168	94.4%	224	209	93.3%
C74	Adrenal gland	5	4	80.0%	3	3	100.0%	8	7	87.5%
C75	Other endocrine	6	5	83.3%	0	0	0.0%	6	5	83.3%
C81	Hodgkin's disease	14	14	100.0%	22	22	100.0%	36	36	100.0%
C82-C85, C96	Non-Hodgkin lymphoma	166	165	99.4%	111	110	99.1%	277	275	99.3%
C90	Multiple myeloma	27	26	96.3%	22	22	100.0%	49	48	98.0%
C91	Lymphoid leukemia	34	32	94.1%	24	21	87.5%	58	53	91.4%
C92-C94	Myeloid leukemia	59	57	96.6%	49	48	98.0%	108	105	97.2%
C95	Leukemia unspecified	5	3	60.0%	8	7	87.5%	13	10	76.9%
O&U(c26,c39,c42,c48,c76,c77,c80,c88)	Other and unspecified	67	45	67.2%	56	31	55.4%	123	76	61.8%
MPO(9960)	Myeloproliferative disorders	2	2	100.0%	1	2	200.0%	3	4	133.3%
MDS(9989)	Myelodysplastic syndromes	2	2	100.0%	0	0	0.0%	2	2	100.0%
	TOTAL	2,716	2,241	82.5%	2,825	2,573	91.1%	5,541	4,814	86.9%

TABLE 9: DISTRIBUTION OF PATIENTS ACCORDING TO TYPE OF TREATMENT

TYPE OF TREATMENT	MALE		FEMALE		TOTAL	
	% IN		% IN			
	NO.	MALES	NO.	FEMALES	NO.	%
Surgery	243	8.9	291	10.3	534	9.6
Radiotherapy	276	10.2	341	12.1	617	11.1
Chemotherapy/hormonal therapy	518	19.1	430	15.2	948	17.1
Surgery + Radiotherapy	116	4.3	142	5.0	258	4.7
Surgery + Chemotherapy/hormonal therapy	103	3.8	266	9.4	369	6.7
Radiotherapy + Chemotherapy/hormonal therapy	80	2.9	204	7.2	284	5.1
Surgery + Radiotherapy + Chemotherapy/hormonal therapy	426	15.7	443	15.7	869	15.7
Best supportive care	954	35.1	708	25.1	1662	30.0
TOTAL	2,716	100.0	2,825	100.0	5,541	100.0

FIGURE 12: TYPES OF TREATMENT




FIGURE 13: TEN-YEAR TRENDS OF CANCER TREATMENT




TABLE 10: THE 10 LEADING SITES OF CANCER IN BOTH SEXES

ICD-10	PRIMARY SITE(Short title used)	NO.	% OF ALL CANCER
C33-C34	Trachea, bronchus and lung	716	12.9
C50	Breast (excluding in situ)	589	10.6
C22	Liver	429	7.7
C53	Cervix uteri (excluding in situ)	388	7.0
C18-C20	Colon and Rectum	373	6.7
C82-C85, C96	Non-Hodgkin lymphoma	277	5.0
C01-C06	Oral cavity	232	4.2
C73	Thyroid	224	4.0
C56	Ovary	185	3.3
C15	Esophagus	176	3.2

FIGURE 14: THE 10 LEADING SITES OF CANCER IN BOTH SEXES




TABLE 11: THE 10 LEADING SITES OF CANCER IN MALES

ICD-10	PRIMARY SITE (Short title used)	NO.	% IN MALES
C33-C34	Trachea, bronchus and lung	482	17.7
C22	Liver	314	11.6
C18-C20	Colon and Rectum	220	8.1
C01-C06	Oral cavity	175	6.4
C82-C85, C96	Non-Hodgkin lymphoma	166	6.1
C15	Esophagus	154	5.7
C32	Larynx	108	4.0
C61	Prostate	106	3.9
C91-C95	Leukemia	98	3.6
C67	Bladder	65	2.4

FIGURE 15: THE 10 LEADING SITES OF CANCER IN MALES




FIGURE 16: TRENDS OF FIVE LEADING SITES IN MALES: NUMBER & PERCENT




TABLE 12: THE 10 LEADING SITES OF CANCER IN FEMALES

ICD-10	PRIMARY SITE (Short title used)	NO.	% IN FEMALES
C50	Breast (excluding in situ)	589	20.9
C53	Cervix uteri (excluding in situ)	388	13.7
C33-C34	Trachea, bronchus and lung	234	8.3
C56	Ovary	185	6.6
C73	Thyroid	178	6.3
C54	Corpus uteri	156	5.5
C18-C20	Colon and Rectum	153	5.4
C22	Liver	115	4.1
C82-C85, C96	Non-Hodgkin lymphoma	111	3.9
C91-C95	Leukemia	81	2.9

FIGURE 17: THE 10 LEADING SITES OF CANCER IN FEMALES




FIGURE 18: TRENDS OF FIVE LEADING SITES IN FEMALES: NUMBER & PERCENT





TABLE 13: MALIGNANCY IN CHILDHOOD (AGE 0-14 YEARS)*

SITE	GROUP (ICCC-3 division)	MALE	FEMALE	TOTAL	
		NO.	NO.	NO.	%
I	Leukemia	21	18	39	33.1
II	Lymphoma	7	6	13	11.0
III	Brain and spinal neoplasms	6	4	10	8.5
IV	Neuroblastoma & Other nervous system tumors	1	3	4	3.4
V	Retinoblastoma	4	2	6	5.1
VI	Renal tumors	0	1	1	0.8
VII	Hepatic tumors	3	0	3	2.5
VIII	Malignant bone tumors	4	5	9	7.6
IX	Soft tissue sarcomas	7	3	10	8.5
X	Germ cell and gonadal neoplasms	5	3	8	6.8
XI	Carcinomas and epithelial neoplasms	0	2	2	1.7
XII	Other and unspecified neoplasms	12	1	13	11.0
Total		70	48	118	100.0

The malignancy in childhood was 2.1% of all new cancer patients.

* Childhood site group according to International Classification of Childhood Cancer, Third edition (ICCC-3)

FIGURE 19: AGE DISTRIBUTION OF ALL MALIGNANCIES IN CHILDHOOD



COMMON CANCERS

ORAL CAVITY CANCER

ICD-10 C01-C06

TABLE 14: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE	FEMALE	TOTAL	%
Clinical only	0	1	1	0.4%
Histology of primary	175	57	232	99.6%
TOTAL	175	57	233	100.0%

FIGURE 20: DISTRIBUTION OF SUBSITES





FIGURE 21: AGE DISTRIBUTION



Male age; Mean 62.21 Median 62

Female age; Mean 66.3 Median 67

ORAL CAVITY CANCER


TABLE 15: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	22	7	29	12.5
Stage II	22	18	40	17.2
Stage III	19	6	25	10.8
Stage IV	95	19	114	48.7
Not specified	17	8	25	10.8
Total	175	58	233	100.0

TABLE 16: TYPES OF TREATMENT

TREATMENT	MALE	FEMALE	TOTAL	%
Surgery	23	3	26	11.2
Radiotherapy	31	11	42	17.7
Chemotherapy	1	0	1	0.4
Surgery + Radiotherapy	23	8	31	13.4
Surgery + Chemotherapy	2	5	7	3.0
Radiotherapy + Chemotherapy	27	8	35	15.1
Surgery + Radiotherapy + Chemotherapy	8	0	8	3.4
Best supportive care	60	23	83	35.8
Total	175	58	233	100.0

FIGURE 22: TRENDS OF ORAL CAVITY CANCER IN MALES AND FEMALES



ESOPHAGEAL CANCER

ICD-10 C15

TABLE 17: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE	FEMALE	TOTAL	%
Clinical investigation and imaging	7	0	7	4.0
Histology of primary	147	22	169	96.0
Total	154	22	176	100.0

FIGURE 23: DISTRIBUTION OF SUBSITES IN BOTH SEXES





FIGURE 24: AGE DISTRIBUTION



Male age; Mean 63.7, Median 64

Female age; Mean 65.9, Median 68

ESOPHAGEAL CANCER


TABLE 18: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage II	1	0	1	0.6
Stage II	5	0	5	2.8
Stage III	44	5	49	27.8
Stage IV	23	1	24	13.6
Not specified	81	16	97	55.1
Total	154	22	176	100.0

TABLE 19: TYPES OF TREATMENT

TREATMENT	MALE	FEMALE	TOTAL	%
Surgery	4	1	5	2.8
Radiotherapy	18	2	20	11.4
Chemotherapy	4	0	4	2.3
Surgery + Radiotherapy	1	0	1	0.6
Surgery + Chemotherapy	0	0	0	0.0
Radiotherapy + Chemotherapy	68	8	76	43.2
Surgery + Radiotherapy + Chemotherapy	7	0	7	4.0
Best supportive care	52	11	63	35.8
Total	154	22	176	100.0

FIGURE 25: TRENDS OF ESOPHAGEAL CANCER IN MALES AND FEMALES



COLON AND RECTUM CANCER

ICD-10 C18-20

TABLE 20: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE	FEMALE	TOTAL	%
Clinical only	2	2	4	1.1
Clinical investigation and imaging	4	4	8	2.1
Specific biochemistry	1	1	2	0.5
Histology of primary	213	146	359	96.2
Total	220	153	373	100.0

FIGURE 26: DISTRIBUTION OF SUBSITES





FIGURE 27: AGE DISTRIBUTION



Male age; Mean 62.3 Median 62
 Female age; Mean 59.2, Median 58

COLON AND RECTUM CANCER

FIGURE 28: AGE DISTRIBUTION TRENDS IN BOTH SEX; 2007-2011





TABLE 21: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	15	9	24	6.4
Stage II	45	41	86	23.1
Stage III	67	41	108	29.0
Stage IV	44	39	83	22.3
Not specified	49	23	72	19.3
Total	220	153	373	100.0

TABLE 22: TYPES OF TREATMENT

TREATMENT	MALE	FEMALE	TOTAL	%
Surgery	35	33	68	20.9
Radiotherapy	8	0	8	2.5
Chemotherapy	19	18	37	11.3
Surgery + Radiotherapy	3	1	4	1.2
Surgery + Chemotherapy	20	28	48	14.7
Radiotherapy + Chemotherapy	15	12	27	8.3
Surgery + Radiotherapy + Chemotherapy	14	15	29	8.9
Best supportive care	62	43	105	32.2
TOTAL	176	150	326	100.0

FIGURE 29: COLON AND RECTUM CANCER TRENDS IN MALES AND FEMALES



LIVER CANCER

ICD-10 C22

TABLE 23: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE	FEMALE	TOTAL	%
Clinical only	10	3	13	3.0
Clinical investigation and imaging	127	49	176	41.0
Surgery without histology	0	0	0	0.0
Specific biochemistry	117	37	154	35.9
Cytology	1	1	2	0.5
Histology of primary	59	25	84	19.6
Total	314	115	429	100.0

FIGURE 30: DISTRIBUTION OF SUBSITES





FIGURE 31: AGE DISTRIBUTION




LIVER CANCER

TABLE 24: TYPES OF TREATMENT

TREATMENT	MALE	FEMALE	TOTAL	%
Surgery	3	3	6	1.4
Radiotherapy	1	0	1	0.2
Chemotherapy	98	32	130	30.3
Surgery + Chemotherapy	5	3	8	1.9
Radiotherapy + Chemotherapy	3	0	3	0.7
Best supportive care	204	77	281	65.5
Total	314	115	429	100.0

FIGURE 32: TRENDS OF LIVER CANCER IN MALES AND FEMALES



LUNG CANCER

ICD-10 C34

TABLE 25: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE	FEMALE	TOTAL	%
Clinical investigation and imaging	39	11	50	7.0
Cytology	8	10	18	2.5
Histology of primary	434	213	647	90.5
Total	481	234	715	100.0

FIGURE 33: DISTRIBUTION OF SUBSITES






FIGURE 34: DISTRIBUTION OF SIDES IN BOTH SEXES



LUNG CANCER

FIGURE 35: AGE DISTRIBUTION



Male age; Mean 63.1, Median 63.0

Female age; Mean 62.1 Median 62.5

TABLE 26: STAGING


STAGE	MALE	FEMALE	TOTAL	%
Stage I	6	5	11	1.5
Stage II	12	3	15	2.1
Stage III	67	25	92	12.8
Stage IV	164	164	328	45.8
Not specified	233	37	270	37.7
Total	482	234	716	100.0

LUNG CANCER

TABLE 27: TYPES OF TREATMENT

TREATMENT	MALE	FEMALE	TOTAL	%
Surgery	7	10	17	2.4
Radiotherapy	45	19	64	9.2
Chemotherapy	145	77	222	31.9
Surgery + Radiotherapy	1	0	1	0.1
Surgery + Chemotherapy	5	8	13	1.9
Radiotherapy + Chemotherapy	74	26	100	14.4
Surgery + Radiotherapy + Chemotherapy	5	2	7	1.0
Best supportive care	180	92	272	39.1
TOTAL	462	234	696	100.0

FIGURE 36: TRENDS OF LUNG CANCER IN MALES AND FEMALES



BREAST CANCER (EXCLUDING IN SITU)

ICD-10 C50

TABLE 28: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	FEMALE	%
Clinical only	1	0.2
Clinical investigation	1	0.2
Cytology	2	0.3
Histology of primary	585	99.3
Total	589	100.0

FIGURE 37: DISTRIBUTION OF SUBSITES






FIGURE 38: AGE DISTRIBUTION



BREAST CANCER (EXCLUDING IN SITU)

FIGURE 39: AGE DISTRIBUTION OF FEMALE BREAST CANCER: 2007-2011



Female age 2007; Mean 49.9, Median 48.5

Female age 2008; Mean 49.5, Median 49.0

Female age 2009; Mean 49.6, Median 49.0

Female age 2010; Mean 50.2, Median 49.0

Female age 2011; Mean 50.8, Median 50.0

FIGURE 40: TRENDS OF FEMALE BREAST CANCER




TABLE 29: STAGING


STAGE	FEMALE	%
Stage I	98	16.6
Stage II	201	34.1
Stage III	148	25.1
Stage IV	62	10.5
Not specified	80	13.6
Total	589	100.0

BREAST CANCER (EXCLUDING IN SITU)

TABLE 30: TYPES OF TREATMENT

TREATMENT	FEMALE	%
Surgery	19	3.2
Radiotherapy	79	13.4
Chemotherapy	40	6.8
hormonal therapy	19	3.2
Chemotherapy + hormonal therapy	10	1.7
Surgery + Radiotherapy	11	1.9
Surgery + Chemotherapy	43	7.3
Surgery + hormonal therapy	12	2.0
Surgery + Chemotherapy + hormonal therapy	41	7.0
Surgery + Radiotherapy + Chemotherapy	51	8.7
Surgery + Radiotherapy + hormonal therapy	11	1.9
Surgery + Radiotherapy + Chemotherapy + hormonal therapy	78	13.2
Radiotherapy + Chemotherapy	43	7.3
Radiotherapy + hormonal therapy	30	5.1
Radiotherapy + Chemotherapy + hormonal therapy	13	2.2
Best supportive care	247	41.9
TOTAL	589	100.0

FIGURE 41: TRENDS OF FEMALE BREAST CANCER STAGING: PERCENTAGE





CERVICAL CANCER (EXCLUDING IN SITU)

ICD-10 C53

TABLE 31: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	NUMBER	%
Clinical investigation	2	0.5
Cytology	1	0.3
Histology of primary	384	99.2
Total	387	100.0

TABLE 32: STAGING

STAGE	NUMBER	%
Stage I	83	21.4
Stage II	144	37.1
Stage III	106	27.3
Stage IV	23	5.9
Not specified	32	8.3
Total	388	100.0

TABLE 33: TYPES OF TREATMENT

TREATMENT	NUMBER	%
Surgery	65	16.8
Radiotherapy	42	10.8
Chemotherapy	3	0.8
Surgery + Radiotherapy	8	2.1
Surgery + Chemotherapy	5	1.3
Radiotherapy + Chemotherapy	188	48.5
Surgery + Radiotherapy + Chemotherapy	12	3.1
Best supportive care	65	16.8
Total	388	100.0

FIGURE 42: AGE DISTRIBUTION




FIGURE 43: AGE DISTRIBUTION OF CERVICAL CANCER: 2007-2011




FIGURE 44: TRENDS OF CERVICAL CANCER





FIGURE 45: TRENDS OF CERVICAL CANCER STAGING: PERCENTAGE



ENDOMETRIAL CANCER

ICD-10 C54

TABLE 34: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	NUMBER	%
Histology of primary	156	100.0
Total	156	100.0

FIGURE 46: AGE DISTRIBUTION





TABLE 35: STAGING

STAGE	NUMBER	%
Stage I	81	51.9
Stage II	15	9.6
Stage III	37	23.7
Stage IV	7	4.5
Not specified	16	10.3
Total	156	100.0

TABLE 36: TYPES OF TREATMENT

TREATMENT	NUMBER	%
Surgery	57	36.5
Radiotherapy	14	9.0
Chemotherapy	3	1.9
Surgery + Radiotherapy	33	21.2
Surgery + Chemotherapy	12	7.7
Radiotherapy + Chemotherapy	7	4.5
Surgery + Radiotherapy + Chemotherapy	15	9.6
Best supportive care	15	9.6
Total	156	100.0

FIGURE 47: TRENDS OF ENDOMETRIAL CANCER



NON-HODGKIN LYMPHOMA

ICD-10 C82-C85, C96

TABLE 37: METHODS OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE	FEMALE	TOTAL	%
Clinical investigation	0	1	1	0.4
Cytology or hematology	1	0	1	0.4
Histology of primary	165	110	275	99.3
Total	166	111	277	100.0

FIGURE 48: AGE DISTRIBUTION




TABLE 38: DISTRIBUTION OF SITES

SITES	MALE	FEMALE	TOTAL	%
Lymph node, NOS	61	43	104	37.5
Skin, NOS	9	7	16	5.8
Tonsil, NOS	8	7	15	5.4
Eye, NOS	9	4	13	4.7
Mediastinum	6	3	9	3.2
Colon, NOS	4	4	8	2.9
Stomach, NOS	4	3	7	2.5
Liver	2	5	7	2.5
Blood	5	2	7	2.5
Soft tissues	3	4	7	2.5



NON-HODGKIN LYMPHOMA(CONT)


SITES	MALE	FEMALE	TOTAL	%
Head, face or neck, NOS	4	3	7	2.5
Brain, NOS	4	2	6	2.2
Nasopharynx, NOS	3	1	4	1.4
Nasal cavity	1	3	4	1.4
Small intestine	2	1	3	1.1
Testis, NOS	3	0	3	1.1
Upper gum	2	0	2	0.7
Palate	2	0	2	0.7
Oropharynx, NOS	1	1	2	0.7
Sinus	2	0	2	0.7
Supraglottis	1	1	2	0.7
Lung, NOS	1	1	2	0.7
Breast, NOS	0	2	2	0.7
Base of tongue, NOS	1	0	1	0.4
Tongue, NOS	1	0	1	0.4
Parotid gland	0	1	1	0.4
Major salivary gland, NOS	1	0	1	0.4
Oesophagus, NOS	1	0	1	0.4
Gastrointestinal tract, NOS	1	0	1	0.4
Bones	1	0	1	0.4
Retroperitoneum	1	0	1	0.4
Cervix uteri	0	1	1	0.4
Endometrium	0	1	1	0.4
Ovary	0	1	1	0.4
Female genital tract, NOS	0	1	1	0.4
Thyroid gland	0	1	1	0.4
Unknown primary site	22	8	30	10.8
Total	166	111	277	100.0

NON-HODGKIN LYMPHOMA

TABLE 39: TYPES OF TREATMENT

TREATMENT	MALE	FEMALE	TOTAL	%
Surgery	0	3	3	1.1
Radiotherapy	8	12	20	7.2
Chemotherapy	87	52	139	50.2
Surgery + Radiotherapy	0	2	2	0.7
Surgery + Chemotherapy	4	0	4	1.4
Radiotherapy + Chemotherapy	15	8	23	8.3
Surgery + Radiotherapy + Chemotherapy	1	0	1	0.4
Best supportive care	51	34	85	30.7
Total	166	111	277	100.0

FIGURE 49: TRENDS OF NON-HODGKIN LYMPHOMA IN MALES AND FEMALES



INTERESTING TUMOR

GASTROINTESTINAL STROMAL TUMOR (GIST)

TABLE 40: NUMBER OF CASES IN 5 YEAR; 2007-2011

YEAR	Male	Female	Total
2007	11	6	17
2008	8	8	16
2009	17	12	29
2010	12	11	23
2011	13	17	30

FIGURE 50: NUMBER OF CASES IN 5 YEAR; 2007-2011




FIGURE 51: AGE DISTRIBUTION; ACCUMULATED 2007-2011






TABLE 41: DISTRIBUTION OF SITES; ACCUMULATED 2007-2011

SITES	Number	%
Stomach	48	41.7
Small Intestine	30	26.1
Intestinal tracts	18	15.7
Colon	5	4.3
Liver	3	2.6
Soft tissue	3	2.6
Rectum	2	1.7
Head of pancreas	2	1.7
Retroperitoneum	1	0.9
Uterus	1	0.9
Bladder	1	0.9
Brain	1	0.9
Total	115	100.0

NEUROENDOCRINE TUMOR (NET)

TABLE 42: NUMBER OF CASES IN 5 YEAR; 2007-2011

YEAR	Male	Female	Total
2007	7	3	10
2008	9	9	18
2009	9	6	15
2010	11	15	26
2011	25	12	37
Total	61	45	106

FIGURE 52: NUMBER OF CASES IN 5 YEAR; 2007-2011




FIGURE 53: AGE DISTRIBUTION; ACCUMULATED 2007-2011






TABLE 43: DISTRIBUTION OF SITES; ACCUMULATED 2007-2011

SITES	Number	%
Lung	19	17.9
Pancreas	14	13.2
Small intestine	7	6.6
Cervix uteri	7	6.6
Unknown primary site	7	6.6
Oesophagus	5	4.7
Colon	5	4.7
Rectum	5	4.7
Mediastinum	5	4.7
Stomach	4	3.8
Breast	4	3.8
Ovary	4	3.8
Gastrointestinal tract	2	1.9
Nasal cavity	2	1.9
Endocrine gland	2	1.9
Nasopharynx	1	0.9
Anal canal	1	0.9
Intrahepatic bile duct	1	0.9
Gallbladder	1	0.9
Ampulla of Vater	1	0.9
Glottis	1	0.9
Skin of trunk	1	0.9
Per. nerves & A.N.S. of abdomen	1	0.9
Vagina	1	0.9
Corpus uteri	1	0.9
Testis	1	0.9
Kidney	1	0.9
Adrenal gland	1	0.9
Abdomen	1	0.9
Total	106	100.0

TABLE 42: SEX AND AGE DISTRIBUTION OF CANCER PATIENT ACCORDING TO PRIMARY SITE

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Lip	Both sex	15	0	0	0	0	0	0	0	0	0	0	1	2	3	0	0	1	2	6
(C00)	Male	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1
	Female	12	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	1	2	5
Tongue	Both sex	111	0	0	0	0	0	1	1	3	8	7	16	12	15	10	17	11	5	5
(C01-C02)	Male	86	0	0	0	0	0	0	1	2	7	5	13	9	11	7	11	11	4	5
	Female	25	0	0	0	0	0	1	0	1	1	2	3	3	4	3	6	0	1	0
Mouth	Both sex	122	0	0	0	0	0	0	3	7	4	13	7	17	8	13	21	16	8	4
(C03-C06)	Male	89	0	0	0	0	0	0	1	7	4	11	4	16	5	9	14	11	4	3
	Female	33	0	0	0	0	0	0	2	0	0	2	3	1	3	4	7	6	4	1
Salivary gland	Both sex	25	0	0	0	1	0	2	0	3	2	2	1	2	5	3	1	3	0	0
(C07-C08)	Male	11	0	0	0	1	0	0	0	0	0	1	1	0	2	2	1	3	0	0
	Female	14	0	0	0	0	0	2	0	3	2	1	0	2	3	1	0	0	0	0
Tonsil	Both sex	36	0	0	0	0	0	0	0	2	1	4	7	2	3	3	6	5	2	1
(C09)	Male	31	0	0	0	0	0	0	0	1	1	3	5	2	3	3	6	4	2	1
	Female	5	0	0	0	0	0	0	0	1	0	1	2	0	0	0	0	1	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Oropharynx	Both sex	24	0	0	0	0	0	0	0	1	2	1	3	3	2	2	4	3	1	2
(C10)	Male	20	0	0	0	0	0	0	0	1	2	0	3	3	1	2	3	3	1	1
	Female	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1
Nasopharynx	Both sex	109	0	0	0	0	1	2	4	11	16	9	19	21	12	7	2	3	2	0
(C11)	Male	81	0	0	0	0	1	1	3	7	12	7	16	16	10	6	0	1	1	0
	Female	28	0	0	0	0	0	1	1	4	4	2	3	5	2	1	2	2	1	0
Hypopharynx	Both sex	71	0	0	0	0	0	0	1	0	2	8	7	7	8	9	10	9	8	2
(C12-C13)	Male	66	0	0	0	0	0	0	1	0	2	7	7	5	8	9	9	8	8	2
	Female	5	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	1	0	0
Pharynx, unspecified	Both sex	6	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	1	1	0
(C14)	Male	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0
	Female	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0
Esophagus	Both sex	176	0	0	0	0	0	0	0	1	7	14	14	27	23	30	25	24	9	2
(C15)	Male	154	0	0	0	0	0	0	0	1	5	12	14	24	22	26	23	18	8	1
	Female	22	0	0	0	0	0	0	0	0	2	2	0	3	1	4	2	6	1	1

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Stomach	Both sex	78	0	0	0	1	0	0	1	2	3	3	6	12	13	16	5	7	8	1
(C16)	Male	49	0	0	0	0	0	0	0	1	2	2	6	7	8	10	3	5	5	0
	Female	29	0	0	0	1	0	0	1	1	1	1	0	5	5	6	2	2	3	1
Small intestine	Both sex	14	0	0	0	0	0	1	1	0	1	0	3	3	0	2	1	1	0	1
(C17)	Male	10	0	0	0	0	0	0	1	0	0	0	3	2	0	2	0	1	0	1
	Female	4	0	0	0	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0
Colon	Both sex	184	0	0	0	0	0	1	3	10	12	9	21	32	16	23	25	14	11	7
(C18)	Male	104	0	0	0	0	0	1	0	4	5	5	10	13	14	15	18	9	9	1
	Female	80	0	0	0	0	0	0	3	6	7	4	11	19	2	8	7	5	2	6
Rectum	Both sex	189	0	0	0	1	0	4	3	8	5	14	16	34	28	22	19	19	9	7
(C19-C20)	Male	116	0	0	0	0	0	3	1	6	2	9	11	16	21	11	13	13	5	5
	Female	73	0	0	0	1	0	1	2	2	3	5	5	18	7	11	6	6	4	2
Anus	Both sex	12	0	0	0	0	0	0	0	0	1	2	1	0	1	3	1	0	0	3
(C21)	Male	5	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0	0	1
	Female	7	0	0	0	0	0	0	0	0	0	2	0	0	0	2	1	0	0	2

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Liver	Both sex	429	2	0	0	0	0	3	6	17	30	45	58	65	59	48	40	27	23	6
(C22)	Male	314	2	0	0	0	0	3	5	15	21	34	47	53	48	34	21	14	14	3
	Female	115	0	0	0	0	0	0	1	2	9	11	11	12	11	14	19	13	9	3
Gallbladder etc.	Both sex	65	0	0	0	0	0	0	1	4	2	4	9	7	8	7	10	6	6	1
(C23-C24)	Male	32	0	0	0	0	0	0	1	0	1	3	5	4	3	2	5	4	3	1
	Female	33	0	0	0	0	0	0	0	4	1	1	4	3	5	5	5	2	3	0
Pancreas	Both sex	91	0	0	0	0	1	0	0	3	2	7	11	13	10	16	8	12	6	2
(C25)	Male	48	0	0	0	0	0	0	0	2	1	5	7	6	4	8	4	8	2	1
	Female	43	0	0	0	0	1	0	0	1	1	2	4	7	6	8	4	4	4	1
Nose, sinuses etc.	Both sex	27	0	0	0	0	0	2	0	1	4	1	3	2	2	3	7	2	0	0
(C30-C31)	Male	14	0	0	0	0	0	1	0	0	1	0	2	2	1	1	4	2	0	0
	Female	13	0	0	0	0	0	1	0	1	3	1	1	0	1	2	3	0	0	0
Larynx	Both sex	110	0	0	0	0	0	0	0	1	2	2	15	13	22	22	14	12	6	1
(C32)	Male	108	0	0	0	0	0	0	0	1	2	2	15	13	22	21	13	12	6	1
	Female	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Trachea, bronchus and lung	Both sex	716	0	0	0	1	0	2	7	18	27	59	87	85	91	94	101	90	38	16
(C33-C34)	Male	482	0	0	0	1	0	0	4	11	15	39	60	57	64	64	67	67	25	8
	Female	234	0	0	0	0	0	2	3	7	12	20	27	28	27	30	34	23	13	8
Other thoracic organs	Both sex	15	0	0	0	1	2	2	3	1	0	1	3	0	1	1	0	0	0	0
(C37-C38)	Male	12	0	0	0	1	2	2	2	1	0	1	2	0	1	0	0	0	0	0
	Female	3	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0
Bone	Both sex	30	0	3	9	6	2	0	2	1	3	0	2	1	0	0	1	1	0	0
(C40-C41)	Male	17	0	2	5	5	0	0	1	1	1	0	1	1	0	0	0	0	0	0
	Female	13	0	1	4	1	2	0	1	0	2	0	1	0	0	0	1	0	0	0
Melanoma of skin	Both sex	24	0	0	0	0	1	0	0	0	1	2	1	3	6	4	3	3	0	0
(C43)	Male	12	0	0	0	0	1	0	0	0	1	2	0	1	3	1	1	2	0	0
	Female	12	0	0	0	0	0	0	0	0	0	0	1	2	3	3	2	1	0	0
Other skin	Both sex	99	0	0	0	2	1	0	2	2	9	5	14	15	8	5	13	9	5	9
(C44)	Male	59	0	0	0	2	1	0	1	1	4	2	10	12	4	2	9	7	1	3
	Female	40	0	0	0	0	0	0	1	1	5	3	4	3	4	3	4	2	4	6

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Connective and soft	Both sex	85	3	2	5	3	2	2	5	2	7	11	9	11	3	6	7	3	1	3
tissues (C47, C49)	Male	44	2	1	4	0	1	2	1	1	4	7	4	6	1	3	3	1	1	2
	Female	41	1	1	1	3	1	0	4	1	3	4	5	5	2	3	4	2	0	1
Breast	Both sex	589	0	0	0	0	1	11	31	53	71	113	111	76	56	25	21	12	7	1
(C50)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	589	0	0	0	0	1	11	31	53	71	113	111	76	56	25	21	12	7	1
Vulva	Both sex	15	0	0	0	0	0	0	1	0	3	0	0	1	0	2	1	4	2	1
(C51)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	15	0	0	0	0	0	0	1	0	3	0	0	1	0	2	1	4	2	1
Vagina	Both sex	11	1	0	0	0	0	0	0	1	0	1	2	3	1	1	1	0	0	0
(C52)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	11	1	0	0	0	0	0	0	1	0	1	2	3	1	1	1	0	0	0
Cervix uteri	Both sex	388	0	0	0	0	2	4	14	40	62	66	59	43	30	22	21	17	8	0
(C53)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	388	0	0	0	0	2	4	14	40	62	66	59	43	30	22	21	17	8	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Corpus uteri	Both sex	156	0	0	0	0	0	0	6	2	9	16	30	38	21	15	9	4	5	1
(C54)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	156	0	0	0	0	0	0	6	2	9	16	30	38	21	15	9	4	5	1
Uterus unspecified	Both sex	15	0	0	0	0	0	2	0	0	0	3	2	3	1	1	1	2	0	0
(C55)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	15	0	0	0	0	0	2	0	0	0	3	2	3	1	1	1	2	0	0
Ovary	Both sex	185	0	0	1	4	12	3	8	7	22	30	25	17	18	18	6	10	2	2
(C56)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	185	0	0	1	4	12	3	8	7	22	30	25	17	18	18	6	10	2	2
Other female genital	Both sex	7	1	0	0	0	0	0	0	1	0	0	0	3	1	0	0	1	0	0
(C57)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	7	1	0	0	0	0	0	0	1	0	0	0	3	1	0	0	1	0	0
Placenta	Both sex	16	0	0	0	2	2	1	1	2	4	1	3	0	0	0	0	0	0	0
(C58)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Female	16	0	0	0	2	2	1	1	2	4	1	3	0	0	0	0	0	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Penis	Both sex	21	0	0	0	0	0	0	0	2	4	1	2	4	2	2	3	1	0	0
(C60)	Male	21	0	0	0	0	0	0	0	2	4	1	2	4	2	2	3	1	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Prostate	Both sex	106	0	0	0	0	0	0	0	0	1	0	1	6	16	13	29	20	10	10
(C61)	Male	106	0	0	0	0	0	0	0	0	1	0	1	6	16	13	29	20	10	10
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Testis	Both sex	12	1	0	0	1	2	1	1	1	2	2	1	0	0	0	0	0	0	0
(C62)	Male	12	1	0	0	1	2	1	1	1	2	2	1	0	0	0	0	0	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other parts of male	Both sex	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
genital organs (C63)	Male	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kidney	Both sex	47	1	2	0	0	0	1	3	1	1	5	4	11	9	1	5	2	1	0
(C64)	Male	33	0	2	0	0	0	0	2	1	0	3	3	9	7	1	2	2	1	0
	Female	14	1	0	0	0	0	1	1	0	1	2	1	2	2	0	3	0	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Renal pelvis	Both sex	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0
(C65)	Male	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ureter	Both sex	6	0	0	0	0	0	0	0	0	0	0	1	0	4	0	1	0	0	0
(C66)	Male	3	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0
	Female	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0
Bladder	Both sex	78	0	0	0	0	0	0	0	0	3	2	7	6	8	7	15	14	10	6
(C67)	Male	65	0	0	0	0	0	0	0	0	2	2	4	5	7	7	14	13	7	4
	Female	13	0	0	0	0	0	0	0	0	1	0	3	1	1	0	1	1	3	2
Other urinary organs	Both sex	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
(C68)	Male	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Eye	Both sex	21	8	1	0	0	0	0	1	2	0	2	1	0	2	0	1	1	1	1
(C69)	Male	10	7	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0
	Female	11	1	1	0	0	0	0	0	2	0	1	1	0	1	0	1	1	1	1

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Brain, nervous system	Both sex	93	6	11	1	4	1	7	6	7	5	12	9	11	8	3	2	0	0	0
(C70-C72)	Male	58	3	9	1	3	1	5	3	2	3	8	6	7	5	0	2	0	0	0
	Female	35	3	2	0	1	0	2	3	5	2	4	3	4	3	3	0	0	0	0
Thyroid	Both sex	224	0	0	2	6	11	8	20	25	30	22	22	23	14	21	10	5	1	4
(C73)	Male	46	0	0	0	0	1	1	5	4	4	6	4	7	3	5	4	1	0	1
	Female	178	0	0	2	6	10	7	15	21	26	16	18	16	11	16	6	4	1	3
Adrenal gland	Both sex	8	4	0	0	0	0	0	0	0	0	0	0	3	0	1	0	0	0	0
(C74)	Male	5	1	0	0	0	0	0	0	0	0	0	0	3	0	1	0	0	0	0
	Female	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other endocrine	Both sex	6	0	1	0	0	2	0	0	0	1	0	0	0	0	0	0	2	0	0
(C75)	Male	6	0	1	0	0	2	0	0	0	1	0	0	0	0	0	0	2	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	Both sex	36	0	2	3	1	6	4	2	2	1	3	4	1	3	1	3	0	0	0
(C81)	Male	14	0	0	1	0	2	2	1	1	1	1	0	0	1	1	3	0	0	0
	Female	22	0	2	2	1	4	2	1	1	0	2	4	1	2	0	0	0	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Non-Hodgkin lymphoma	Both sex	277	3	3	2	8	3	6	13	16	14	34	26	33	25	25	27	22	13	4
(C82-C85, C96)	Male	166	2	2	2	6	2	2	8	6	8	16	15	23	20	16	14	12	8	4
	Female	111	1	1	0	2	1	4	5	10	6	18	11	10	5	9	13	10	5	0
Multiple myeloma	Both sex	49	0	0	0	0	0	0	1	0	4	4	3	7	6	7	10	5	2	0
(C90)	Male	27	0	0	0	0	0	0	1	0	2	2	2	6	3	1	6	2	2	0
	Female	22	0	0	0	0	0	0	0	0	2	2	1	1	3	6	4	3	0	0
Lymphoid leukemia	Both sex	56	15	6	6	4	0	3	0	3	3	1	2	1	2	3	6	0	2	1
(C91)	Male	34	8	3	2	3	0	3	0	2	1	1	1	1	2	3	3	0	1	0
	Female	24	7	3	4	1	0	0	0	1	2	0	1	0	0	0	3	0	1	1
Myeloid leukemia	Both sex	108	6	2	2	12	5	2	8	4	8	8	9	4	11	13	8	2	3	1
(C92-C94)	Male	59	4	2	1	7	3	0	5	3	5	3	6	2	4	8	3	0	2	1
	Female	49	2	0	1	5	2	2	3	1	3	5	3	2	7	5	5	2	1	0
Leukemia unspecified	Both sex	13	0	1	1	0	0	0	0	0	1	1	0	2	1	1	1	3	1	0
(C95)	Male	5	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0
	Female	8	0	0	1	0	0	0	0	0	1	1	0	2	1	1	0	1	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Non-Hodgkin lymphoma	Both sex	277	3	3	2	8	3	6	13	16	14	34	26	33	25	25	27	22	13	4
(C82-C85, C96)	Male	166	2	2	2	6	2	2	8	6	8	16	15	23	20	16	14	12	8	4
	Female	111	1	1	0	2	1	4	5	10	6	18	11	10	5	9	13	10	5	0
Multiple myeloma	Both sex	49	0	0	0	0	0	0	1	0	4	4	3	7	6	7	10	5	2	0
(C90)	Male	27	0	0	0	0	0	0	1	0	2	2	2	6	3	1	6	2	2	0
	Female	22	0	0	0	0	0	0	0	0	2	2	1	1	3	6	4	3	0	0
Lymphoid leukemia	Both sex	56	15	6	6	4	0	3	0	3	3	1	2	1	2	3	6	0	2	1
(C91)	Male	34	8	3	2	3	0	3	0	2	1	1	1	1	2	3	3	0	1	0
	Female	24	7	3	4	1	0	0	0	1	2	0	1	0	0	0	3	0	1	1
Myeloid leukemia	Both sex	108	6	2	2	12	5	2	8	4	8	8	9	4	11	13	8	2	3	1
(C92-C94)	Male	59	4	2	1	7	3	0	5	3	5	3	6	2	4	8	3	0	2	1
	Female	49	2	0	1	5	2	2	3	1	3	5	3	2	7	5	5	2	1	0
Leukemia unspecified	Both sex	13	0	1	1	0	0	0	0	0	1	1	0	2	1	1	1	3	1	0
(C95)	Male	5	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0
	Female	8	0	0	1	0	0	0	0	0	1	1	0	2	1	1	0	1	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Non-Hodgkin lymphoma	Both sex	277	3	3	2	8	3	6	13	16	14	34	26	33	25	25	27	22	13	4
(C82-C85, C96)	Male	166	2	2	2	6	2	2	8	6	8	16	15	23	20	16	14	12	8	4
	Female	111	1	1	0	2	1	4	5	10	6	18	11	10	5	9	13	10	5	0
Multiple myeloma	Both sex	49	0	0	0	0	0	0	1	0	4	4	3	7	6	7	10	5	2	0
(C90)	Male	27	0	0	0	0	0	0	1	0	2	2	2	6	3	1	6	2	2	0
	Female	22	0	0	0	0	0	0	0	0	2	2	1	1	3	6	4	3	0	0
Lymphoid leukemia	Both sex	56	15	6	6	4	0	3	0	3	3	1	2	1	2	3	6	0	2	1
(C91)	Male	34	8	3	2	3	0	3	0	2	1	1	1	1	2	3	3	0	1	0
	Female	24	7	3	4	1	0	0	0	1	2	0	1	0	0	0	3	0	1	1
Myeloid leukemia	Both sex	108	6	2	2	12	5	2	8	4	8	8	9	4	11	13	8	2	3	1
(C92-C94)	Male	59	4	2	1	7	3	0	5	3	5	3	6	2	4	8	3	0	2	1
	Female	49	2	0	1	5	2	2	3	1	3	5	3	2	7	5	5	2	1	0
Leukemia unspecified	Both sex	13	0	1	1	0	0	0	0	0	1	1	0	2	1	1	1	3	1	0
(C95)	Male	5	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0
	Female	8	0	0	1	0	0	0	0	0	1	1	0	2	1	1	0	1	0	0

PRIMARY SITE (ICD-10)	SEX	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Other & unspecified	Both sex	123	1	0	0	0	2	1	3	2	4	11	10	12	22	17	20	7	6	5
(C26, C39, C48, C76, C77, C80)	Male	67	1	0	0	0	0	0	1	2	2	8	4	6	14	8	10	4	5	2
	Female	56	0	0	0	0	2	1	2	0	2	3	6	6	8	9	10	3	1	3
Myeloproliferative disorders	Both sex	3	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0
(MPD) M 995_/3, M 996_/3	Male	2	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0
	Female	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Myelodysplastic syndromes	Both sex	2	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
(MDS) M 998_/3	Male	2	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
	Female	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
All sites	Both sex	5,541	52	34	32	58	59	77	163	269	404	562	670	698	610	550	545	417	225	116
	Male	2,716	31	23	16	30	19	28	52	87	130	212	300	348	346	307	323	264	137	63
	Female	2,825	21	11	16	28	40	49	111	182	274	350	370	350	264	243	222	153	88	53

TABLE 45: HISTOLOGICAL TYPES

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
Lip			3	12	15
(C00)	8051	Verrucous carcinoma, NOS	1	2	3
	8070	Squamous cell carcinoma, NOS	2	10	12
Tongue			86	25	111
(C01-C02)	8010	Carcinoma, NOS	1	0	1
	8070	Squamous cell carcinoma, NOS	83	23	106
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	1	0	1
	8074	Squamous cell carcinoma, spindle cell	1	0	1
	8200	Adenoid cystic carcinoma	0	1	1
	8430	Mucoepidermoid carcinoma	0	1	1
Mouth			89	33	122
(C03-C06)	8000	Clinical, no microscopic confirmation	0	1	1
	8000	Neoplasm, malignant	2	0	2
	8002	Malignant tumor, small cell type	0	1	1
	8070	Squamous cell carcinoma, NOS	83	27	110
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8200	Adenoid cystic carcinoma	1	2	3
	8310	Clear cell adenocarcinoma, NOS	1	0	1
	8430	Mucoepidermoid carcinoma	1	1	2
	8830	Malignant fibrous histiocyoma	0	1	1
Salivary gland			11	14	25
(C07-C08)	8010	Carcinoma, NOS	1	0	1
	8012	Large cell carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	1	2	3
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8082	Lymphoepithelial carcinoma	0	2	2
	8083	Basaloid squamous cell carcinoma	1	0	1

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8140	Adenocarcinoma, NOS	1	0	1
	8200	Adenoid cystic carcinoma	0	3	3
	8430	Mucoepidermoid carcinoma	4	6	10
	8480	Mucinous adenocarcinoma	1	0	1
	8550	Acinar cell carcinoma	1	0	1
Tonsil		Total	31	5	36
(C09)	8000	Clinical, no microscopic confirmation	0	1	1
	8070	Squamous cell carcinoma, NOS	31	4	35
Oropharynx		Total	20	4	24
(C10)	8070	Squamous cell carcinoma, NOS	20	4	24
Nasopharynx		Total	81	28	109
(C11)	8000	Clinical, no microscopic confirmation	0	1	1
	8000	Neoplasm, malignant	2	0	2
	8020	Carcinoma, undifferentiated, NOS	24	5	29
	8070	Squamous cell carcinoma, NOS	32	12	44
	8071	Squamous cell carcinoma, keratinizing, NOS	2	0	2
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	20	9	29
	8200	Adenoid cystic carcinoma	0	1	1
	8246	Neuroendocrine carcinoma, NOS	1	0	1
Hypopharynx		Total	66	5	71
(C12-C13)	8070	Squamous cell carcinoma, NOS	66	4	70
	8082	Lymphoepithelial carcinoma	0	1	1
Pharynx, unspecified		Total	3	3	6
(C14)	8051	Verrucous carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	3	2	5

PRIMARY SITE	MORPHOLOGY	MORPHOLOGY	MALE	FEMALE	ALL	
(ICD-10)	CODE					
Esophagus			Total	154	22	176
(C15)	8000	Clinical, no microscopic confirmation	7	0	7	
	8000	Neoplasm, malignant	3	0	3	
	8070	Squamous cell carcinoma, NOS	136	22	158	
	8140	Adenocarcinoma, NOS	5	0	5	
	8246	Neuroendocrine carcinoma, NOS	2	0	2	
	8490	Signet ring cell carcinoma	1	0	1	
Stomach			Total	49	29	78
(C16)	8000	Clinical, no microscopic confirmation	1	1	2	
	8070	Squamous cell carcinoma, NOS	2	2	4	
	8140	Adenocarcinoma, NOS	39	21	60	
	8240	Carcinoid tumor, NOS	1	2	3	
	8490	Signet ring cell carcinoma	6	3	9	
Small intestine			Total	10	4	14
(C17)	8000	Clinical, no microscopic confirmation	2	1	3	
	8140	Adenocarcinoma, NOS	4	2	6	
	8240	Carcinoid tumor, NOS	3	0	3	
	8890	Leiomyosarcoma, NOS	0	1	1	
	8936	Gastrointestinal stromal tumor	1	0	1	
Colon			Total	104	80	184
(C18)	8000	clinical, no microscopic confirmation	3	7	10	
	8000	Neoplasm, malignant	5	4	9	
	8140	Adenocarcinoma, NOS	88	60	148	
	8246	Neuroendocrine carcinoma, NOS	2	0	2	
	8480	Mucinous adenocarcinoma	2	4	6	
	8481	Mucin-producing adenocarcinoma	1	0	1	
	8490	Signet ring cell carcinoma	3	3	6	
	8560	Adenosquamous carcinoma	0	1	1	
	9540	Malignant peripheral nerve sheath tumor	0	1		
		Meningeal sarcomatosis				

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
Rectum		Total	116	73	189
(C19-C20)	8000	Clinical, no microscopic confirmation	4	0	4
	8000	Neoplasm, malignant	2	0	2
	8013	Large cell neuroendocrine carcinoma	1	0	1
	8140	Adenocarcinoma, NOS	107	72	179
	8240	Carcinoid tumor, NOS	1	0	1
	8480	Mucinous adenocarcinoma	1	0	1
	8490	Signet ring cell carcinoma	0	1	1
Anus		Total	5	7	12
(C21)	8000	Neoplasm, malignant	0	1	1
	8070	Squamous cell carcinoma, NOS	1	2	3
	8140	Adenocarcinoma, NOS	4	3	7
	8890	Leiomyosarcoma, NOS	0	1	1
Liver		Total	314	115	429
(C22)	8000	Clinical, no microscopic confirmation	254	89	343
	8000	Neoplasm, malignant	2	3	5
	8010	Carcinoma, NOS	1	0	1
	8012	Large cell carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	10	5	15
	8160	Cholangiocarcinoma	4	2	6
	8170	Hepatocellular carcinoma, NOS	41	16	57
	8970	Hepatoblastoma	1	0	1
Gallbladder etc.		Total	32	33	65
(C23-C24)	8000	Clinical, no microscopic confirmation	8	7	15
	8000	Neoplasm, malignant	1	2	3
	8010	Carcinoma, NOS	1	0	1
	8070	Squamous cell carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	19	21	40
	8246	Neuroendocrine carcinoma, NOS	1	0	1

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
--------------------------	--------------------	------------	------	--------	-----

	8260	Papillary adenocarcinoma, NOS	0	3	3
	8560	Adenosquamous carcinoma	1	0	1

Pancreas			Total	48	43	91
(C25)	8000	Clinical, no microscopic confirmation	25	21	46	
	8000	Neoplasm, malignant	3	2	5	
	8010	Carcinoma, NOS	1	2	3	
	8020	Carcinoma, undifferentiated, NOS	0	1	1	
	8046	Non-small cell carcinoma	0	1	1	
	8140	Adenocarcinoma, NOS	17	13	30	
	8246	Neuroendocrine carcinoma, NOS	2	2	4	
	8550	Acinar cell carcinoma	0	1	1	

Nose, sinuses etc.			Total	14	13	27
(C30-C31)	8000	Clinical, no microscopic confirmation	1	0	1	
	8020	Carcinoma, undifferentiated, NOS	1	2	3	
	8070	Squamous cell carcinoma, NOS	11	5	16	
	8071	Squamous cell carcinoma, keratinizing, NOS	0	1	1	
	8200	Adenoid cystic carcinoma	0	2	2	
	8680	Paraganglioma, malignant	1	0	1	
	8900	Rhabdomyosarcoma, NOS	0	1	1	
	8920	Alveolar rhabdomyosarcoma	0	1	1	
	9500	Neuroblastoma, NOS	0	1	1	

Larynx			Total	108	2	110
(C32)	8000	Clinical, no microscopic confirmation		0	1	1
	8000	Neoplasm, malignant		6	0	6
	8020	Carcinoma, undifferentiated, NOS		1	0	1
	8070	Squamous cell carcinoma, NOS		99	1	100
	8074	Squamous cell carcinoma, spindle cell		1	0	1
	8801	Spindle cell sarcoma		1	0	1

PRIMARY SITE	MORPHOLOGY	MORPHOLOGY	MALE	FEMALE	ALL	
(ICD-10)	CODE					
Trachea, bronchus and lung			Total	482	234	716
(C33-C34)	8000	Clinical, no microscopic confirmation	40	11	51	
	8000	Neoplasm, malignant	8	3	11	
	8010	Carcinoma, NOS	14	3	17	
	8012	Large cell carcinoma, NOS	4	0	4	
	8013	Large cell neuroendocrine carcinoma	1	0	1	
	8014	Large cell carcinoma with rhabdoid phenotype	1	0	1	
	8020	Carcinoma, undifferentiated, NOS	6	1	7	
	8041	Small cell carcinoma, NOS	43	2	45	
	8046	Non-small cell carcinoma	42	12	54	
	8070	Squamous cell carcinoma, NOS	86	14	100	
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1	
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	1	0	1	
	8140	Adenocarcinoma, NOS	222	168	390	
	8240	Carcinoid tumor, NOS	0	1	1	
	8246	Neuroendocrine carcinoma, NOS	4	0	4	
	8250	Bronchiolo-alveolar adenocarcinoma, NOS	7	16	23	
	8430	Mucoepidermoid carcinoma	1	1	2	
	8490	Signet ring cell carcinoma	0	1	1	
	8560	Adenosquamous carcinoma	1	0	1	
	9050	Mesothelioma, malignant	0	1	1	
Other thoracic			Total	12	3	15
organs (C37-C38)	8000	Clinical, no microscopic confirmation	1	1	2	
	8000	Neoplasm, malignant	2	1	3	
	8041	Small cell carcinoma, NOS	1	0	1	
	8246	Neuroendocrine carcinoma, NOS	2	1	3	
	8580	Thymoma, malignant, NOS	1	0	1	
	9060	Dysgerminoma	1	0	1	
	9061	Seminoma, NOS	1	0	1	
	9071	Endodermal sinus tumor (Yolk sac tumor)	1	0	1	

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
	9080	Immature teratoma, malignant	1	0	1
	9085	Mixed germ cell tumor	1	0	1

Bone			Total	17	13	30
(C40-C41)	8000	Clinical, no microscopic confirmation		6	2	8
	8010	Carcinoma, NOS		0	1	1
	8032	Spindle cell carcinoma, NOS		0	1	1
	8802	Pleomorphic sarcoma		0	1	1
	8803	Small cell sarcoma		1	0	1
	9150	Hemangiopericytoma, malignant		0	1	1
	9180	Osteosarcoma, NOS		6	5	11
	9250	Giant cell tumor of bone, malignant		1	0	1
	9260	Ewing sarcoma		2	2	4
	9473	Primitive neuroectodermal tumor, NOS		1	0	1

Melanoma of skin			Total	12	12	24
(C43)	8720	Malignant melanoma, NOS		12	11	23
	8773	Spindle cell melanoma, type A		0	1	1

Other skin			Total	59	40	99
(C44)	8000	Neoplasm, malignant		1	0	1
	8005	Malignant tumor, clear cell type		1	0	1
	8010	Carcinoma, NOS		1	0	1
	8070	Squamous cell carcinoma, NOS		34	11	45
	8090	Basal cell carcinoma, NOS		14	20	34
	8097	Basal cell carcinoma, nodular		1	0	1
	8103	Pilar tumor		0	1	1
	8200	Adenoid cystic carcinoma		0	1	1
	8410	Sebaceous adenocarcinoma		3	1	4
	8420	Ceruminous adenocarcinoma		0	1	1
	8542	Paget disease, extramammary (ex. Paget dis.of bone)		1	0	1

PRIMARY SITE	MORPHOLOGY	MORPHOLOGY	MALE	FEMALE	ALL	
(ICD-10)	CODE					
	8802	Pleomorphic sarcoma	0	0	0	
	8832	Dermatofibrosarcoma, NOS	3	5	8	
Connective and			Total	44	42	86
soft tissues	8000	Clinical, no microscopic confirmation	1	5	6	
(C47, C49)	8010	Carcinoma, NOS	1	0	1	
	8020	Carcinoma, undifferentiated, NOS	1	0	1	
	8032	Spindle cell carcinoma, NOS	0	1	1	
	8801	Spindle cell sarcoma	5	2	7	
	8802	Pleomorphic sarcoma	4	4	8	
	8803	Small cell sarcoma	0	1	1	
	8810	Fibrosarcoma, NOS	0	1	1	
	8830	Malignant fibrous histiocytoma	4	6	10	
	8850	Liposarcoma, NOS	6	2	8	
	8852	Myxoid liposarcoma	5	0	5	
	8854	Pleomorphic liposarcoma	1	0	1	
	8858	Dedifferentiated liposarcoma	1	0	1	
	8890	Leiomyosarcoma, NOS	3	4	7	
	8900	Rhabdomyosarcoma, NOS	2	2	4	
	8901	Pleomorphic rhabdomyosarcoma, adult type	1	0	1	
	8910	Embryonal rhabdomyosarcoma, NOS	0	2	2	
	8912	Spindle cell rhabdomyosarcoma	1	0	1	
	8920	Alveolar rhabdomyosarcoma	1	1	2	
	9040	Synovial sarcoma, NOS	1	2	3	
	9041	Synovial sarcoma, spindle cell	1	0	1	
	9080	Immature teratoma, malignant	1	0	1	
	9120	Hemangiosarcoma	0	1	1	
	9220	Chondrosarcoma, NOS	0	1	1	
	9260	Ewing sarcoma	1	2	3	
	9540	Malignant peripheral nerve sheath	2	3	5	
		tumorMeningeal sarcomatosis				
	9560	Neurilemoma, malignant	1	2	3	



PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
Breast			Total	0	589
				589	589
(C50)	8000	Clinical, no microscopic confirmation	0	2	2
	8000	Neoplasm, malignant	0	30	30
	8010	Carcinoma, NOS	0	6	6
	8020	Carcinoma, undifferentiated, NOS	0	1	1
	8050	Papillary carcinoma, NOS	0	1	1
	8140	Adenocarcinoma, NOS	0	9	9
	8200	Adenoid cystic carcinoma	0	1	1
	8246	Neuroendocrine carcinoma, NOS	0	1	1
	8260	Papillary adenocarcinoma, NOS	0	1	1
	8480	Mucinous adenocarcinoma	0	14	14
	8500	Infiltrating duct carcinoma, NOS	0	481	481
	8510	Medullary carcinoma, NOS	0	4	4
	8520	Lobular carcinoma, NOS	0	22	22
	8522	Infiltrating duct and lobular carcinoma	0	3	3
	8523	Infiltrating duct mixed with other carcinoma	0	2	2
	8540	Paget disease, mammary	0	1	1
	8543	Paget disease and intraductal carcinoma of breast	0	1	1
	8575	Metaplastic carcinoma, NOS	0	2	2
	8810	Fibrosarcoma, NOS	0	1	1
	8980	Carcinosarcoma, NOS	0	1	1
	9020	Phyllodes tumor, malignant	0	5	5
Vulva			Total	0	15
				15	15
(C51)	8000	Clinical, no microscopic confirmation	0	1	1
	8070	Squamous cell carcinoma, NOS	0	9	9
	8094	Basosquamous carcinoma	0	1	1
	8542	Paget disease, extramammary (ex. Paget dis.of bone)	0	3	3
	8772	Spindle cell melanoma, NOS	0	1	1

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
Vagina			Total	0	11
(C52)	8010	Carcinoma, NOS	0	1	1
	8052	Papillary squamous cell carcinoma	0	1	1
	8070	Squamous cell carcinoma, NOS	0	5	5
	8140	Adenocarcinoma, NOS	0	2	2
	8246	Neuroendocrine carcinoma, NOS	0	1	1
	9071	Endodermal sinus tumor (Yolk sac tumor)	0	1	1
Cervix uteri			Total	0	388
(C53)	8000	Clinical, no microscopic confirmation	0	2	2
	8000	Neoplasm, malignant	0	6	6
	8010	Carcinoma, NOS	0	3	3
	8041	Small cell carcinoma, NOS	0	8	8
	8045	Combined small cell carcinoma	0	1	1
	8052	Papillary squamous cell carcinoma	0	1	1
	8070	Squamous cell carcinoma, NOS	0	229	229
	8071	Squamous cell carcinoma, keratinizing, NOS	0	8	8
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	0	29	29
	8076	Squamous cell carcinoma, microinvasive	0	19	19
	8140	Adenocarcinoma, NOS	0	69	69
	8246	Neuroendocrine carcinoma, NOS	0	2	2
	8310	Clear cell adenocarcinoma, NOS	0	1	1
	8560	Adenosquamous carcinoma	0	9	9
	8910	Embryonal rhabdomyosarcoma, NOS	0	1	1
Corpus uteri			Total	0	156
(C54)	8000	Neoplasm, malignant	0	1	1
	8010	Carcinoma, NOS	0	2	2
	8070	Squamous cell carcinoma, NOS	0	1	1
	8140	Adenocarcinoma, NOS	0	16	16
	8310	Clear cell adenocarcinoma, NOS	0	2	2
	8323	Mixed cell adenocarcinoma	0	3	3

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8380	Endometrioid adenocarcinoma, NOS	0	116	116
	8383	Endometrioid adenocarcinoma, ciliated cell variant	0	1	1
	8441	Serous cystadenocarcinoma, NOS	0	6	6
	8560	Adenosquamous carcinoma	0	1	1
	8890	Leiomyosarcoma, NOS	0	1	1
	8930	Endometrial stromal sarcoma, NOS	0	2	2
	8980	Carcinosarcoma, NOS	0	4	4

Uterus unspecified		Total	0	15	15
(C55)	8000	Neoplasm, malignant	0	1	1
	8041	Small cell carcinoma, NOS	0	1	1
	8800	Sarcoma, NOS	0	1	1
	8802	Pleomorphic sarcoma	0	1	1
	8852	Myxoid liposarcoma	0	1	1
	8890	Leiomyosarcoma, NOS	0	5	5
	8910	Embryonal rhabdomyosarcoma, NOS	0	1	1
	8980	Carcinosarcoma, NOS	0	3	3
	9041	Synovial sarcoma, spindle cell	0	1	1

Ovary		Total	0	185	185
(C56)	8000	Clinical, no microscopic confirmation	0	11	11
	8000	Neoplasm, malignant	0	1	1
	8013	Large cell neuroendocrine carcinoma	0	1	1
	8041	Small cell carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	0	3	3
	8140	Adenocarcinoma, NOS	0	32	32
	8246	Neuroendocrine carcinoma, NOS	0	1	1
	8260	Papillary adenocarcinoma, NOS	0	1	1
	8310	Clear cell adenocarcinoma, NOS	0	21	21
	8323	Mixed cell adenocarcinoma	0	2	2
	8380	Endometrioid adenocarcinoma, NOS	0	17	17
	8441	Serous cystadenocarcinoma, NOS	0	42	42

PRIMARY SITE	MORPHOLOGY	MORPHOLOGY	MALE	FEMALE	ALL
(ICD-10)	CODE				
	8460	Papillary serous cystadenocarcinoma	0	12	12
	8470	Mucinous cystadenocarcinoma, NOS	0	6	6
	8471	Papillary mucinous cystadenocarcinoma	0	1	1
	8480	Mucinous adenocarcinoma	0	13	13
	8801	Spindle cell sarcoma	0	1	1
	8806	Desmoplastic small round cell tumor	0	1	1
	8815	Solitary fibrous tumor, malignant	0	1	1
	8980	Carcinosarcoma, NOS	0	1	1
	9060	Dysgerminoma	0	5	5
	9071	Endodermal sinus tumor (Yolk sac tumor)	0	3	3
	9080	Immature teratoma, malignant	0	7	7
	9085	Mixed germ cell tumor	0	1	1
Other female			Total	0	7
genital	8000	Neoplasm, malignant	0	1	1
(C57)	8070	Squamous cell carcinoma, NOS	0	1	1
	8140	Adenocarcinoma, NOS	0	1	1
	8380	Endometrioid adenocarcinoma, NOS	0	1	1
	8441	Serous cystadenocarcinoma, NOS	0	1	1
	8460	Papillary serous cystadenocarcinoma	0	1	1
	9071	Endodermal sinus tumor (Yolk sac tumor)	0	1	1
Placenta			Total	0	16
(C58)	8000	Clinical, no microscopic confirmation	0	9	9
	9100	Choriocarcinoma, NOS	0	7	7
Penis			Total	21	0
(C60)	8000	Clinical, no microscopic confirmation	1	0	1
	8000	Neoplasm, malignant	1	0	1
	8070	Squamous cell carcinoma, NOS	19	0	19

PRIMARY SITE	MORPHOLOGY	MORPHOLOGY	MALE	FEMALE	ALL	
(ICD-10)	CODE					
Prostate			Total	106	0	106
(C61)	8000	Clinical, no microscopic confirmation	12	0	12	
	8000	Neoplasm, malignant	5	0	5	
	8010	Carcinoma, NOS	2	0	2	
	8033	Pseudosarcomatous carcinoma	1	0	1	
	8140	Adenocarcinoma, NOS	86	0	86	
Testis			Total	12	0	12
(C62)	8000	Clinical, no microscopic confirmation	3	0	3	
	8801	Spindle cell sarcoma	1	0	1	
	9061	Seminoma, NOS	4	0	4	
	9070	Embryonal carcinoma, NOS	2	0	2	
	9085	Mixed germ cell tumor	1	0	1	
	9100	Choriocarcinoma, NOS	1	0	1	
Other parts of male genital organs			Total	1	0	1
(C63)	8070	Squamous cell carcinoma, NOS	1	0	1	
Kidney			Total	33	14	47
(C64)	8000	Clinical, no microscopic confirmation	6	2	8	
	8000	Neoplasm, malignant	1	1	2	
	8010	Carcinoma, NOS	1	0	1	
	8130	Papillary transitional cell carcinoma	1	0	1	
	8140	Adenocarcinoma, NOS	3	1	4	
	8260	Papillary adenocarcinoma, NOS	0	1	1	
	8312	Renal cell carcinoma, NOS	17	7	24	
	8317	Renal cell carcinoma, chromophobe type	1	0	1	
	8319	Collecting duct carcinoma	0	1	1	
	8960	Nephroblastoma, NOS	1	1	2	
	8964	Clear cell sarcoma of kidney	1	0	1	
	9260	Ewing sarcoma	1	0	1	

PRIMARY SITE	MORPHOLOGY	MORPHOLOGY	MALE	FEMALE	ALL	
(ICD-10)	CODE					
Renal pelvis			Total	3	0	3
(C65)	8120	Transitional cell carcinoma, NOS	2	0	2	
	8312	Renal cell carcinoma, NOS	1	0	1	
Ureter			Total	3	3	6
(C66)	8000	Clinical, no microscopic confirmation	0	2	2	
	8120	Transitional cell carcinoma, NOS	3	1	4	
Bladder			Total	9	6	15
(C67)	8000	Clinical, no microscopic confirmation	1	1	2	
	8000	Neoplasm, malignant	1	0	1	
	8070	Squamous cell carcinoma, NOS	1	0	1	
	8120	Transitional cell carcinoma, NOS	39	8	47	
	8122	Transitional cell carcinoma, spindle cell	1	0	1	
	8130	Papillary transitional cell carcinoma	21	2	23	
	8140	Adenocarcinoma, NOS	1	2	3	
Other urinary organs			Total	1	0	1
(C68)	8070	Squamous cell carcinoma, NOS	1	0	1	
Eye			Total	10	11	21
(C69)	8000	Clinical, no microscopic confirmation	3	2	5	
	8000	Neoplasm, malignant	0	1	1	
	8070	Squamous cell carcinoma, NOS	1	5	6	
	8076	Squamous cell carcinoma, microinvasive	1	0	1	
	8720	Malignant melanoma, NOS	1	1	2	
	9510	Retinoblastoma, NOS	4	2	6	
Brain, nervous			Total	58	35	93
system	8000	Clinical, no microscopic confirmation	11	4	15	
(C70-C72)	8000	Neoplasm, malignant	1	0	1	
	8720	Malignant melanoma, NOS	0	1	1	
	8811	Fibromyxosarcoma	1	0	1	

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
	9064	Germinoma	1	0	1
	9080	Immature teratoma, malignant	1	0	1
	9382	Mixed glioma	0	3	3
	9390	Choroid plexus carcinoma	0	1	1
	9391	Ependymoma, NOS	0	2	2
	9392	Ependymoma, anaplastic	0	1	1
	9400	Astrocytoma, NOS	9	3	12
	9401	Astrocytoma, anaplastic	3	2	5
	9440	Glioblastoma, NOS	22	14	36
	9450	Oligodendroglioma, NOS	2	0	2
	9451	Oligodendroglioma, anaplastic	3	1	4
	9470	Medulloblastoma, NOS	3	1	4
	9471	Desmoplastic nodular medulloblastoma	1	0	1
	9508	Atypical teratoid/rhabdoid tumor	0	1	1
	9530	Meningioma, malignant	0	1	1

Thyroid			Total	46	178	224
(C73)	8000	Clinical, no microscopic confirmation	1	1	2	
	8000	Neoplasm, malignant	3	3	6	
	8010	Carcinoma, NOS	0	1	1	
	8021	Carcinoma, anaplastic, NOS	2	4	6	
	8022	Pleomorphic carcinoma	0	1	1	
	8071	Squamous cell carcinoma, keratinizing, NOS	0	1	1	
	8260	Papillary adenocarcinoma, NOS	29	129	158	
	8290	Oxyphilic adenocarcinoma	0	1	1	
	8330	Follicular adenocarcinoma, NOS	6	28	34	
	8337	Insular carcinoma	1	1	2	
	8340	Papillary carcinoma, follicular variant	1	2	3	
	8341	Papillary microcarcinoma	0	6	6	
	8510	Medullary carcinoma, NOS	3	0	3	

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
Adrenal gland			5	3	8
Total					
(C74)	8000	Clinical, no microscopic confirmation	1	0	1
	8000	Neoplasm, malignant	1	0	1
	8010	Carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	1	0	1
	9500	Neuroblastoma, NOS	1	3	4
Other endocrine			6	0	6
Total					
(C75)	8000	Clinical, no microscopic confirmation	1	0	1
	8246	Neuroendocrine carcinoma, NOS	1	0	1
	8247	Merkel cell carcinoma	1	0	1
	9080	Immature teratoma, malignant	1	0	1
	9085	Mixed germ cell tumor	1	0	1
	9401	Astrocytoma, anaplastic	1	0	1
Hodgkin lymphoma			14	22	36
Total					
(C81)	9650	Hodgkin lymphoma, NOS	4	0	4
	9651	Hodgkin lymphoma, lymphocyte-rich	1	1	2
	9652	Hodgkin lymphoma, mixed cellularity, NOS	3	6	9
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	1	3	4
	9663	Hodgkin lymphoma, nodular sclerosis, NOS	5	11	16
	9666	H. dis.,nodular scler.,mixed cellularity	0	1	1
Non-Hodgkin			166	111	277
Total					
lymphoma (C82-C85, C96)	9590	Malignant lymphoma, NOS	1	3	4
	9591	Malignant lymphoma, non-Hodgkin, NOS	8	3	11
	9670	Malignant lymphoma, small B lymphocytic, NOS	4	0	4
	9671	Malignant lymphoma, lymphoplasmacytic	3	1	4
	9673	Mantle cell lymphoma	7	0	7
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	86	67	153
	9684	Malig.lymphoma,large B-cell,diffuse,immunoblas.NOS	1	0	1
	9687	Burkitt lymphoma, NOS	4	2	6

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL	
	9689	Splenic marginal zone B-cell lymphoma	1	1	2	
	9690	Follicular lymphoma, NOS	4	1	5	
	9691	Follicular lymphoma, grade 2	0	1	1	
	9695	Follicular lymphoma, grade 1	0	3	3	
	9698	Follicular lymphoma, grade 3	4	1	5	
	9699	Marginal zone B-cell lymphoma, NOS	11	9	20	
	9702	Peripheral T-cell lymphoma, NOS	17	10	27	
	9705	Angioimmunoblastic T-cell lymphoma	4	2	6	
	9709	Cutaneous T-cell lymphoma, NOS	5	1	6	
	9714	Anaplastic large cell lymphoma, T cell/null cell type	1	4	5	
	9719	NK/T-cell lymphoma, nasal and nasal-type	3	0	3	
	9727	Precursor cell lymphoblastic lymphoma, NOS	1	0	1	
	9729	Precursor T-cell lymphoblastic lymphoma	1	2	3	
Multiple myeloma			Total	27	22	49
(C90)	9731	Plasmacytoma, NOS	3	2	5	
	9732	Multiple myeloma	24	19	43	
	9734	Plasmacytoma(not occurring in bone)	0	1	1	
Lymphoid leukemia			Total	34	24	58
(C91)	9823	B-cell chronic lymphocytic leukemia/small lymphocyt.lymphoma	9	4	13	
	9835	Acute lymphoblastic leukemia, NOS	25	20	45	
Myeloid leukemia			Total	59	49	108
(C92-C94)	9840	Acute myeloid leukemia, M6 type	1	0	1	
	9860	Myeloid leukemia, NOS	0	1	1	
	9861	Acute myeloid leukemia, NOS	28	20	48	
	9863	Chronic myeloid leukemia, NOS	17	18	35	
	9866	Acute promyelocytic leukemia-M3	1	2	3	
	9867	Acute myelomonocytic leukemia	1	3	4	
	9872	Acute myeloid leukemia, minimal differentiation	1	0	1	

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL
	9873	Acute myeloid leukemia without maturation	3	1	4
	9874	Acute myeloid leukemia with maturation	3	3	6
	9891	Acute monocytic leukemia	3	0	3
	9910	Acute megakaryoblastic leukemia	0	1	1
	9930	Myeloid sarcoma	1	0	1

Leukemia		Total	5	8	13
unspecified	9801	Acute leukemia, NOS	4	6	10
(C95)	9800	Leukemia, NOS	1	2	3

Other & unspecified		Total	67	56	123
(C26, C39, C42,	8000	Clinical, no microscopic confirmation	16	17	33
C48, C76, C77,	8000	Neoplasm, malignant	5	1	6
C80)	8010	Carcinoma, NOS	6	4	10
	8020	Carcinoma, undifferentiated, NOS	1	1	2
	8032	Spindle cell carcinoma, NOS	0	2	2
	8041	Small cell carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	12	7	19
	8140	Adenocarcinoma, NOS	20	18	38
	8246	Neuroendocrine carcinoma, NOS	2	0	2
	8310	Clear cell adenocarcinoma, NOS	0	1	1
	8441	Serous cystadenocarcinoma, NOS	0	4	4
	8481	Mucin-producing adenocarcinoma	1	0	1
	8773	Spindle cell melanoma, type A	0	0	0
	8806	Desmoplastic small round cell tumor	1	0	1
	8890	Leiomyosarcoma, NOS	1	0	1
	9071	Endodermal sinus tumor (Yolk sac tumor)	1	0	1
	9761	Waldenstrom macroglobulinemia	1	0	1



ANNUAL REPORT 2011

PRIMARY SITE (ICD-10)	MORPHOLOGY CODE	MORPHOLOGY	MALE	FEMALE	ALL	
Myeloproliferative disorders			Total	2	1	3
(MPD) m 995_/3,						
m 996_/3	9960	Chronic myeloproliferative disease, NOS	2	1	3	
Myelodysplastic syndromes			Total	2	0	2
(MDS) m 998_/3	9989	Myelodysplastic syndrome, NOS	2	0	2	

APPENDIX: DEFINITIONS

NEW CASE	Cancer case diagnosed at Songklanagarind Hospital or referred to Songklanagarind Hospital in the year reported.
CANCER CASE	Excluding <i>in situ</i> neoplasms.
INTERESTING TUMOR	Report only gastrointestinal tumor and neuroendocrine tumor.
TREATMENT	Treatment given at Songklanagarind hospital not including treatment received previously.
BRAIN TUMOR	Excluding meningeal and cranial nerve tumor.
NOS.	Not Otherwise Specified.
CODING	Topography according to the ICD-10, and morphology according to the ICD-O, third edition, coding in childhood based on International Classification of Childhood Cancer, Third edition (ICCC-3).